Please assess the completion status of the following clinical trial:

Trial Title: Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult s (18 80 years) with HCC and who refused surgical resection~2. Tumour number not more than five and the largest tumour size not larger than 5.0 cm;~3. Ill defined lesions which are not easily detected on grey scale USG for lesion targeting.~4. Liver function status at Child Pugh class A or B;~5. East Coast Oncology Group (ECOG) performance status value 0 or 1;~6. No severe coagulopathy (e.g. platelets ≥50,000/ prothrombin time ratio ≥ 50%).~7. Available medical records and/or imaging studies.~Exclusion Criteria:~1. Presence of vascular invasion and extrahepatic metastases at pre procedure imaging study;~2. Ongoing anticoagulant treatment that cannot be stopped;~3. Combined TACE and ablation for a larger lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patients undergoing ablation for HCC (Type: EXPERIMENTAL): Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).